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Research
Over the past half‑century, methodologic 
advances have provided an increasingly strong 
quantitative basis for estimating the human 
health risks associated with exposures to envi‑
ronmental contaminants. Estimation of the 
dose–response function is one of four critical 
elements of the now paradigmatic approach to 
health risk assessment developed in 1983 by 
the National Research Council (NRC 1983). 
Establishing dose–response functions fre‑
quently requires extrapolating limited amounts 
of data from high‑concentration animal tox‑
icologic studies to the relatively lower con‑
centrations typically experienced by humans. 
Statistical methods, known as “low‑dose 
extrapolation” models, have been developed for 
this purpose, and their merits and limitations 
have been debated since the earliest efforts in 
environmental contaminant risk assessment.
Recent advancements in statistical 
methods have allowed for more robust epi‑
demiologic evaluation of very large popula‑
tions exposed to environmental pollutants 
at ambient concentrations, thus providing 
information that informs low‑dose extrapola‑
tion issues. In studied populations, thresholds 
have not generally been observed for cancer 
or, more notably, noncancer outcomes. This 
observation derives primarily from studies of 
radiation (NRC 1999, 2005), secondhand 
tobacco smoke [U.S. Department of Health 
and Human Services (U.S. DHHS) 2004], 
nitrogen and sulfur oxides [U.S. Environmental 
Protection Agency (EPA) 2008a, 2008b], par‑
ticulate matter (U.S. EPA 2006b), ozone (U.S. 
EPA 2006a), and lead (U.S. EPA 2006c). These 
studies have spurred reconsideration of the can‑
cer and noncancer paradigms used to extrapo‑
late dose–response relationships for the relatively 
low doses of environmental toxicants typically 
encountered in the ambient environment.
The U.S. EPA and the Johns Hopkins Risk 
Sciences and Public Policy Institute (RSPPI) 
organized a workshop, titled “State‑of‑the‑
Science Workshop: Issues and Approaches 
in Low Dose–Response Extrapolation for 
Environmental Health Risk Assessment,” held 
23–24 April 2007 in Baltimore, Maryland. 
Participants included 17 experts from diverse 
disciplines, including toxicology, biostatistics, 
human biology, epidemiology, and risk assess‑
ment (see Appendix 1). Workshop background 
materials, prepared by RSPPI, focused on 
a literature review on low‑dose extrapolation, 
including extensively characterized examples of 
observed human responses at low ambient expo‑
sure levels. Workshop goals were to a) review 
the state of the science for high‑ to low‑dose–
response extrapolation methods in environmen‑
tal health risk assessments, b) identify realistic 
approaches for the practical application of low‑
dose extrapolation incorporating the relevant 
scientific evidence to the fullest extent feasible, 
and c) identify areas for future work.
Workshop Issues
Participants identified two key issues specifi‑
cally related to the application of low‑dose 
extrapolation methods in risk assessments of 
environmental pollutants: a) definition of 
mode of action (MOA) and sufficiency of data 
to determine MOA and b) the implications, 
for dose–response model selection, of inter‑
individual variability and risk additivity from 
background disease processes and exposures 
for both cancer and noncancer outcomes.
Defining and Assessing MOA
Using MOA information has become increas‑
ingly prominent in risk assessment. Recent 
U.S. EPA documents on human health risk 
assessment and selection of low‑dose extrapo‑
lation approaches emphasize the use of MOA 
data in characterizing dose–response relation‑
ships for both cancer and noncancer outcomes 
(U.S. EPA 2004, 2005). In these documents, 
mode of action is contrasted with mechanism 
of action, with the latter term implying a 
more detailed understanding of key biological 
events, typically at the molecular level.
Comprehensive approaches for evaluat‑
ing the evidence to support selection of any 
particular MOA have not yet been fully devel‑
oped. To date, efforts of the International 
Programme on Chemical Safety (IPCS) 
(Boobis et al. 2006) and the International 
Life Sciences Institute (Meek et al. 2003) have 
focused on frameworks to evaluate MOAs and 
the human relevance of animal tumor data for 
human exposures to carcinogens. An IPCS 
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framework for evaluating the human relevance 
of noncancer MOAs is under development 
(IPCS 2006). Well‑established systematic evi‑
dence gathering, assessment, and synthesis 
processes have been widely applied in other 
domains such as clinical medicine and pub‑
lic health (e.g., the Cochrane Collaboration 
reviews, http://www.cochrane.org). Processes 
for the conduct of such systematic reviews of 
evidence are important for characterizing the 
strength of evidence to support an association 
or effect. Standard terminology developed to 
describe the strength of epidemiologic evidence 
supporting disease causation (e.g., Hill 1965) 
has been implemented in reports such as the 
U.S. Surgeon General’s reports on the health 
consequences of smoking (e.g., U.S. DHHS 
2004). These efforts can be useful in devel‑
oping a comprehensive strength‑of‑evidence 
approach for MOA both for cancer (U.S. 
EPA 2005) and noncancer (U.S. EPA 2008a, 
2008b). Guyton et al. (2008) further elaborate 
on MOA definitional and evidentiary issues.
Approaches to Low-Dose–Response 
Extrapolation
Participants proposed several modifications 
to current practice of low‑dose extrapola‑
tion model selection during the workshop 
discussion that they generally thought bet‑
ter reflected recent methods in epidemiology 
and statistics and, in several instances, more 
probabilistic descriptions of risk. The first 
approach illustrates how MOA categories can 
be better conceptualized to facilitate quantita‑
tive assessment. The next three approaches are 
inference based (as opposed to MOA based) 
and include a conceptual model that explicitly 
incorporates both variability and uncertainty 
to better estimate population dose–response, 
arguments for linear low‑dose extrapolation 
as the default, and inclusion of severity in the 
standard uncertainty factor (UF) approach. 
These approaches are presented approximately 
in decreasing order of complexity. Lastly, 
we discuss model averaging to better reflect 
uncertainty in model selection.
Categorical approach to low-dose extrapo-
lation using MOA information. Advances in 
basic sciences are increasing biological under‑
standing of disease processes and providing 
the foundation for more biologically informed 
frameworks of quantitative risk estimation. 
However, current understanding of specific 
biological responses from exposure to par‑
ticular chemicals, and how sensitivity changes 
with age, is relatively limited. Understanding 
mechanisms of action is generally so data 
intensive that progress has been difficult, 
whereas MOAs, as currently conceptualized 
and described, are often so general as to not 
inform quantitative models.
The first conceptual approach focuses 
on a small number of broadly defined MOA 
categories, using evidence from both the chemi‑
cal and general literatures on the MOA biology 
to develop generic dose–response models for 
each category. MOA categories and models 
could be developed by examining a) the revers‑
ibility of the chemical’s action on the biologi‑
cal system at low doses or at preclinical stages 
of developing biological responses and, b) if 
reversible, the rate of repair or, c) if irreversible, 
the numbers of unreversed/unrepaired damage 
steps needed to produce clinically detectable 
harm. Data gaps associated with the MOA(s) 
for an individual chemical could be bridged 
with information from other chemicals within 
the MOA category. For example, the approach 
might include three MOA categories, such as 
low‑dose reversible mechanisms (e.g., irritation), 
small numbers of generally irreversible events 
(e.g., mutations), and large numbers of chronic 
cumulative, irreversible events (e.g., neuronal 
loss leading to Parkinsonism). It would not 
exclude other descriptions of MOAs, but would 
focus efforts on the most common and well‑
understood disease processes and the attributes 
of importance to modeling dose–response (for 
further discussion, see Hattis et al. 2008).
Inference-based models for low-dose 
extrapo  lation. The complex molecular and cel‑
lular events that underlie the actions of agents 
that lead to cancer and noncancer outcomes are 
likely to be both linear and nonlinear. At the 
human population level, however, biological 
and statistical attributes tend to smooth and 
linearize the dose–response relationship, obscur‑
ing thresholds that might exist for individuals. 
Most notable of these attributes are population 
variability, additivity to preexisting disease or 
disease processes, and background exposure–
induced disease processes. (Measurement error 
also undoubtedly contributes to this phenom‑
enon.) The linear appearance of the population‑
level dose–response function does not presume 
that the dose–response relationship is neces‑
sarily linear for individuals (Lutz 1990, 2001; 
Lutz et al. 2005), but may reflect a distribution 
of individual thresholds. These attributes are 
likely to explain, at least in part, why exposure–
response models of the relationship between 
cancer or noncancer health effects and expo‑
sure to environmental toxicants with relatively 
robust human health effects databases at ambi‑
ent concentrations (e.g., ozone and particulate 
matter air pollution, lead, secondhand tobacco 
smoke, radiation) do not exhibit evident thresh‑
olds, even though the MOAs include nonlinear 
processes for key events (NRC 2005; U.S. EPA 
2006a, 2006b, 2006c; U.S. DHHS 2004). 
These attributes of human population dose–
response relationships have been extensively 
discussed in the broader epidemiologic litera‑
ture (e.g., Rothman and Greenland 2008) but 
not often in conjunction with using animal 
data to estimate human risks. Discussions at the 
workshop led to several proposed dose–response 
models described below, based on the above 
considerations.
Low-dose modeling incorporating uncer-
tainty and variability. Participants discussed 
a quantitative modeling approach that more 
explicitly accounts for both uncertainty and 
variability in estimating low‑dose risk (see 
Appendix 2 for expanded description). This 
approach can be used for cases where single 
or multiple MOAs are involved and a sto‑
chastic linear process dominates the biological 
disease process for relatively low doses. It can 
also be applied in cases where the slope of the 
dose–response relationship in the observable 
range may differ from the low‑dose slope if, 
for example, multiple MOAs contributed to 
the dose–response relationship in the observ‑
able range but at low doses one MOA was 
considerably more dominant. A variant of the 
approach can be used to characterize popula‑
tion dose–response relationships resulting from 
the inclusion of individuals with distinct thresh‑
olds (see Appendix 2, Equations 1 and 2). This 
approach incorporates variables to account for 
uncertainties related to animal‑to‑human and 
high‑ to low‑dose extrapolations, as well as 
interindividual human variation. The goal is to 
support statements such as, “The risk of effect 
does not exceed x level for the yth percentile 
individual, stated with confidence of z%.” Such 
expressions of risk are more robust than what is 
typically available.
Linear low-dose extrapolation from the 
range of observed responses. Issues regarding 
current default conventions typically applied 
to exposure–response relationships for most 
“toxic” pollutants (i.e., linear, no‑threshold 
assumption for cancer outcomes and a thresh‑
old for noncancer outcomes) versus the con‑
vention used for several ambient air pollutants, 
secondhand tobacco smoke, and radiation (i.e., 
linear, no‑threshold assumption for cancer and 
noncancer outcomes) received considerable 
discussion. Participants generally concurred 
that modeling approaches using a linear, no‑
threshold assumption improved consideration 
of the population‑level factors (noted above) 
for both cancer and noncancer end points.
Participants noted the use of specific bio‑
logical knowledge to adjust the slope of the 
dose–response estimate as a variant of this 
approach worthy of further exploration. For 
example, if the dose–response function was 
based on rodent data, and if humans were less 
sensitive than rodents at some key event in the 
disease process, then the slope of the function 
could be adjusted accordingly, based on com‑
parative species sensitivities. This adjustment 
could be done semiqualitatively absent robust 
data to make precise adjustments.
Modification of the EPA uncertainty factor 
(UF) approach. The current default approach to 
low‑dose extrapolation for noncancer outcomes 
divides either a no‑observed‑adverse‑effect level Low-dose extrapolation workshop report
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(NOAEL) or a lowest‑observed‑adverse‑effect 
level (LOAEL) or, preferably, a statistically cal‑
culated point of departure (an estimate of the 
lower end of the range of observed responses) 
by selected UFs, for example, a UF of 10 for 
human‑to‑animal extrapolation. A proposed 
modification of this approach discussed by par‑
ticipants includes an additional UF to account 
for severity of health effects, a modification that 
is not considered in the current approach. The 
primary advantage of the UF approach versus 
modeling is that it more effectively communi‑
cates that quantitative low‑dose extrapolation is 
uncertain under almost any circumstance.
Low-dose extrapolation model selection. 
Model selection is one significant source of 
uncertainty in extrapolating low‑dose risks. It 
has long been recognized that alternative mod‑
els may lead to strikingly different estimates 
that vary, for example, by the assumption of a 
threshold or of linearity or nonlinearity (e.g., 
Meier et al. 1993; Portier 2000). Workshop 
participants discussed the concept of model 
averaging as a statistical approach to inform 
model selection. Model averaging does not 
require selecting a single model. It acknowl‑
edges the uncertainties associated with model 
selection and allows for incorporation of any 
prior information that would lead to particular 
weights for a suitable, usually large, specified 
set of models that are often weighted equally 
a priori. Posterior model probabilities are then 
computed for the individual models, reflecting 
the likelihood that a model holds, given the 
observed data. Model results are then averaged 
with respect to the posterior probabilities, giv‑
ing greater weight to those best fitting the data 
(e.g., Raftery et al. 1997). External information 
may also be used in specifying prior weights.
Workshop Findings
Concluding discussions provided a general 
consensus on answers to several key ques‑
tions and highlighted areas where oppor‑
tunities exist for enhancing low‑dose risk 
extrapolation methods. These included 
improvements to the risk extrapolation pro‑
cess by refining existing, or developing new, 
procedures, in part drawing on approaches 
already used in public health decision mak‑
ing. Finally, participants identified gaps in 
the science that might be filled with a tar‑
geted research initiative.
Harmonization of cancer and noncancer 
risk models and an inference-based approach. 
Workshop participants were uniformly of the 
view that the dichotomy between low‑dose–
response extrapolation methods typically 
applied to cancer and noncancer outcomes is 
not useful. Currently, in the absence of con‑
vincing chemical‑specific evidence, low‑dose 
linearity without a threshold is assumed for car‑
cinogens, whereas noncarcinogens are generally 
considered to have thresholds. The approaches 
used to characterize their dose–response rela‑
tionships reflect these assumptions. Participants 
proposed that the dichotomy be set aside and 
concluded that selection of low‑dose extrapo‑
lation models be informed by categorization 
of mechanisms of toxicity, such as genotoxic, 
epigenetic, or cytotoxic processes, and by popu‑
lation‑level factors (e.g., susceptibility).
Almost all workshop participants preferred 
a linear, no‑threshold approach to low‑dose 
extrapolation, combined with modeled esti‑
mates of the low range of the observed data 
(e.g., benchmark dose modeling), for both 
cancer and noncancer outcomes. We discuss 
this in more detail below. A small minority 
of participants expressed some reservation 
regarding selection of a linear nonthreshold 
dose–response function as the default model 
assumption for cancer and noncancer outcomes 
given information on human biologic processes 
such as reversibility and repair.
MOA-based models. Although emphasis 
on using MOA‑based models qualitatively has 
increased, much less attention has been given 
to translating the understanding of MOA into 
quantitative estimates or useful models for low‑
dose extrapolation. In the cancer paradigm, the 
multistage theory of carcinogenesis has pro‑
vided the basis for developing corresponding 
statistical models. For noncancer outcomes, 
a broad range of specific and nonspecific 
MOAs are relevant to model development. 
Additionally, noncancer end points are likely 
to be complex and involve multiple interde‑
pendent physiologic changes. Interdisciplinary 
consideration of this issue is needed, perhaps 
for each of the major classes of MOAs, because 
many biologic processes are relevant to both 
cancer and noncancer health outcomes.
Using MOA to inform dose–response 
modeling holds substantial promise, and 
there are potentially numerous ways to con‑
ceptualize MOAs. Extensive multidisciplinary 
collaboration among biologists, toxicologists, 
epidemiologists, and statisticians will be needed 
to identify MOAs that describe the biological 
dose–response process in a manner that is infor‑
mative for modeling. Participants recognized 
that successful development of this approach will 
likely extend beyond the near term. At least one 
workshop participant expressed concern that 
practical biologically informed dose–response 
modeling is unlikely for the foreseeable future 
owing to the complexities of disease processes.
Inference-based model selection. Most, 
but not all, workshop participants concluded 
that for population‑level risk analyses, in the 
absence of MOA‑based dose–response models, 
the most appropriate low‑dose extrapolation 
approach for both cancer and noncancer end 
points is linear, no‑threshold extrapolation 
from the range of observed responses, recog‑
nizing the effects of population variability as 
well as additivity to background disease and 
exposures on the dose–response function. 
The inference that the population response at 
low doses would increase linearly with dose 
is drawn primarily from the impact on mod‑
eled dose–response relationships of these fac‑
tors and is not inconsistent with the existence 
of individual thresholds. Extensive observa‑
tional data to evaluate low‑dose response in 
humans are available currently for only a few 
environmental agents. However, available data 
support use of linear, no‑threshold low‑dose 
extrapolation, unless there are sufficient data 
to select an alternative model.
Assumptions regarding excess and back-
ground risks. The choice of the under‑
lying model to use in considering how 
additional risk from an exposure combines 
with other factors (i.e., the determinants of the 
Appendix 1: State-of-the-Science Workshop:  
Issues and Approaches in Low Dose–Response Extrapolation 
for Environmental Health Risk Assessment, 23–24 April 2007, 
Baltimore, Maryland, USA
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Fox, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; Seymour 
Garte, University of Pittsburgh Cancer Institute, Pittsburgh, PA; Dale B. Hattis, 
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“background risk”) often remains uncertain. 
Sufficient confidence in the understanding 
of MOA for both the background determi‑
nants and the agent of interest is needed to 
address this issue with any certainty. Absent 
such knowledge, risk assessors often default to 
a multiplicative effect of the exposure of inter‑
est on background risk, in part for computa‑
tional convenience. Workshop participants 
suggested that sensitivity analyses may be used 
to explore the consequences of assuming addi‑
tivity to background risk or other alternatives.
Participants noted that, because of the 
paucity of mechanistic information to inform 
selection of disease categories, many mech‑
anistically dissimilar diseases may be added 
incorrectly to background risks. In some situ‑
ations, the additivity assumption may not be 
useful, for example, when toxicity is associated 
with high doses of essential elements or when 
adaptive capabilities at various levels of bio‑
logical organization are sufficient to modulate 
responses to environmental stressors at the 
population level.
Integrated models drawing on human 
and animal data. The workshop participants 
agreed that risk models might be enhanced if 
both human and animal data could be used 
collectively, to inform the model. The devel‑
opment of models that integrate informa‑
tion from both human and animal data hold 
potential for improving the precision of low‑
dose extrapolation models.
Population variability. The theme of 
incorporating population variability into 
dose–response assessment and low‑dose 
extrapolation was prominent in workshop dis‑
cussions. The increasing understanding of the 
significance of interindividual variability for 
population‑level low‑dose extrapolation mod‑
eling was reflected in several of the approaches 
presented at the workshop.
Workshop Recommendations
Development of an operational definition of 
an MOA. Although the concept of MOA 
is inherently useful for risk assessment, cur‑
rent definitions lack specificity for selecting 
low‑dose extrapolation models. Blurred defi‑
nitional lines exist between mode of action, 
posed as a pragmatically useful level of under‑
standing of “key events” involved in specific 
health outcomes, and mechanism of action, 
which implies a deeper, more deterministic 
Appendix 2: Linear Low-Dose Framework 
Incorporating Uncertainty and Variability
This model estimates low‑dose human risk building on the slope of the 
dose–response function at the benchmark dose (Equation 1). The slope 
of the dose–response relationship in the observable range could differ 
from the low‑dose slope if, for example, multiple MOAs contributed 
to the dose–response relationship in the observable range but at low 
doses one MOA was considerably more dominant. To account for this 
difference in low‑dose slope, the slope at the benchmark dose could be 
modified by a factor MS, an adjustment factor based on mechanistic 
understanding. When linearity is expected to dominate from the lower 
end of the observed dose–response relationship to lower doses, MS takes 
on a value of 1. Low‑dose risk could be expressed as
  RiskH = SlopeBMD × MS × FH–A × D,  [1]
where RiskH is the low‑dose human risk, SlopeBMD is the slope of the 
dose–response curve at what would be chosen as the benchmark dose 
under the current practice, MS adjusts for the differences in slope at 
the high doses compared with low doses (0 ≤ MS ≤ 1), FH–A adjusts 
for interspecies differences, and D is the dose.
FH–A is typically expressed as two factors to account for human–
animal differences: one in pharmacokinetics and the other in pharma‑
codynamics: FH–A = FH–A PK × FH–A PD. In cases where cross‑species 
differences in pharmacokinetics were used to derive the SlopeBMD, 
the FH–A would be represented by FH–A PD.
Each of the factors in Equation 1 may represent a model, a single 
number, or a distribution, depending on the nature of the data and 
the goal of the analysis.
Persons can differ considerably in susceptibility to effects from 
toxicants for many reasons, including genetics, lifestyle, health status, 
and background exposures. Uncertainty lies in each of the factors 
given in Equation 1 above, as well as in our understanding of the 
degree of variability in susceptibility. The following provides a frame‑
work to account for both uncertainty and variability in estimating 
low‑dose risk for Equation 1. The goal is to enable the expressions 
such as, “The risk of effect does not exceed x level for the yth percen‑
tile individual, stated with confidence of z%.”
Uncertainty. To address the uncertainty, a random variable U is 
introduced into Equation 1 as a means of formally accounting for 
uncertainty:
  RiskH = SlopeBMD × MS × FH–A × D × U.  [2]
The distribution of U would be specified and would depend on 
the analysis being performed. An alternative, and the conventional, 
approach would be to simply express each factor in Equation 1 as a 
random variable, and not introduce U.
In certain cases, it may be convenient and appropriate to describe 
uncertainty in RiskH mathematically with a lognormal distribution 
as a default if, for example, the uncertainty in each of the factors in 
Equation 1 can be represented by a lognormal distribution. In this 
case, Equation 2 may be restated as
  Log RiskH = log SlopeBMD + log MS + log FH–A + log D + u,  [3]
where the random variable u is distributed normally with mean 0 and 
variance σ2. Thus, for this simplistic case,






Variability. For some toxicity processes with multiple MOAs, 
such as cancer, which involve cell proliferation and mutation MOAs, 
the low‑dose linearity may be dominated by a stochastic process that 
results in linear dose–response relationships for exposed individual 
persons. In this case, variability and MS may be essentially indepen‑
dent at low doses. In this case, the risk for the yth percentile indi‑
vidual is given by
  RiskH yth = SlopeBMD × MS × FH–A × D × VH yth × U,  [5]
where VH yth is the yth quantile of the distribution that describes the 
ratio of the yth percentile individual to the median individual. If the 
uncertainty in the VH yth and the other elements of the uncertainty 
are described by a lognormal distribution, the overall uncertainty 
represented by σ2 would be described by adding a term σlogV
2 to 
the terms given in Equation 4 above. This would not necessarily be 
the case if the low‑dose linearity arises at the population level from 
processes that at the individual level involve threshold responses. The 
MS and variability VH would then not be independent. In this case, 
descriptions of population risk and uncertainty using Equations 1 
and 2 could be developed, as well as exploration of risk in the more 
susceptible segments of the population.Low-dose extrapolation workshop report
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knowledge of the exposure–disease process. If 
the MOA concept is to be universally appli‑
cable in risk assessment, the general guidance 
currently offered to define MOA should be 
made more specific and include expanded def‑
initional language to improve application in 
risk assessments.
Development of approaches for evaluating 
and synthesizing evidence on MOA. Workshop 
participants recommended extending method‑
ology to determine the level of evidence to 
support a particular MOA. A standardized 
process that is transparent and replicable for 
gathering, reviewing, and synthesizing evi‑
dence should be developed. A hierarchical 
classification of the evidence for a particular 
MOA should also be developed, potentially 
drawing on existing approaches. This might be 
tested in side‑by‑side comparisons with several 
agents that have been assessed using existing 
approaches.
Incorporation of variability, background 
incidence, and background exposures into 
current models. Current dose–response mod‑
els could be refined to include more explicit 
consideration of population variability, back‑
ground disease incidence, and background 
exposures. Population and/or chemical specific 
data should be used when available.
Use of model-averaging approaches. 
Participants recommended Bayesian model 
averaging as one approach to addressing 
model selection and suggested model aver‑
aging as an approach for considering the 
consequences of analytic model selection 
for risk characterization.
Areas of Suggested Further 
Research
Develop and test process for characterizing level 
of evidence for MOA. There is a critical need 
to develop criteria to evaluate, and a frame‑
work to classify, strength of evidence related 
to determining an MOA given the increasing 
emphasis on using MOA‑based dose–response 
approaches. Application of evidence criteria 
and the related classification framework to 
real‑world examples of chemical case studies is 
necessary to ensure the approaches’ utility.
Explore variability in the human pop-
ulation relative to animal populations. A 
better understanding of the nature of, and 
biologic bases for, the variability in human 
health responses associated with environmen‑
tal contaminant exposures that can reflect 
differences in underlying genetic composi‑
tion in populations, social factors, and/or 
preexisting disease status is needed to inform 
future improvements to dose–response mod‑
els. Improved animal models of human dis‑
ease states, and of genetic and physiologic 
variability, will also be needed to provide 
dose–response data relevant to the biologic 
variability of human populations.
Support a methodologic research agenda. 
Apply MOA information to models. The 
anticipated scientific advances in under‑
standing MOAs for classes of chemicals will 
require translation into dose–response mod‑
els for chemical risk assessments. If realized, 
these scientific advances hold promise for 
developing relevant MOA‑based categorical 
approaches to dose–response modeling.
Explore  statistical  approaches  to 
model selection. Improvements to statisti‑
cal approaches for model selection, such as 
model averaging, should be pursued. Case 
study applications of these advanced statisti‑
cal approaches will identify potential strengths 
and weaknesses of these approaches and their 
significance for risk characterization.
Consider background risk. Expanded 
understanding of MOAs for environmental 
contaminants and biologic bases for disease 
processes could inform efforts to improve 
dose–response models that integrate back‑
ground disease risks with pollutant exposures.
Develop hybrid modeling approaches. 
Increased efforts are needed to develop mod‑
eling approaches that integrate data for mul‑
tiple species and health end points.
Conclusions
This workshop report presents recommenda‑
tions for advancing the science and practice of 
low‑dose  –response extrapolation for assessing 
and characterizing population health risks from 
exposures to environmental contaminants.
A common assumption when extrapolating 
experimental animal data to estimated human 
responses at low doses is that if nonlinear or 
dose‑transitional key events in an MOA are 
identified, then an actual or practical threshold 
exists. Although this may be true for individu‑
als, its applicability to large population is less 
certain. Population variability, as well as the 
potential for additivity with other preexisting 
background disease processes or exposures, is an 
inherent component of large‑population dose–
response relationships that influences consid‑
eration of no‑threshold low‑dose–response 
models. Therefore, it is difficult to draw con‑
clusions about the shape of the dose–response 
function for the general population from MOA 
information alone. Well‑researched examples 
from the epidemiologic literature regarding, 
for example, particulate matter, ozone, lead, 
secondhand tobacco smoke, and radon rein‑
force the need for updating dose–response 
assessment procedures for extrapolating dose–
response models to low‑dose exposures, par‑
ticularly regarding continued application of the 
threshold dose–response as an inference‑based 
model for noncancer outcomes.
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